News
PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020
PETAH TIKVA, Israel, Oct. 28, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it...
PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results
Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100 from FDA Presented Positive Phase 2 Results of D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery at ASCRS Meeting Completed...
PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020
PETAH TIKVA, Israel, Aug. 05, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it...
PolyPid Granted Fast Track Designation from FDA for D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery
PETAH TIKVA, Israel, Aug. 03, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that...
PolyPid to Present Phase 2 Results of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions
PETAH TIKVA, Israel, July 27, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that...
PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections
PETAH TIKVA, Israel, July 1, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the...
PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PETAH TIKVA, Israel, June 30, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the closing of...
PolyPid Ltd. Announces Pricing of Initial Public Offering
PETAH TIKVA, Israel, June 26, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the pricing of...